Pharma Industry Decision Quality ROI
Click to enlarge
During the seven years of portfolio DA adoption across the Pharmaceutical Industry, we tracked the Adopters Index against the DJ Pharma Index and the much broader S&P 500 Index.
"In the end we learned that our portfolio was worth $2.6 billion more than it was when we started. This was powerful confirmation that our efforts were worthwhile."
- – Paul Sharpe, VP SmithKline Beecham
"I estimate the extra cost to SB for this effort was $2 Million.
So the payoff was 1300 to 1.